Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus APTENSIO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus APTENSIO XR.
ADDERALL 5 vs APTENSIO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Central alpha-2 adrenergic agonist that selectively stimulates alpha-2 adrenergic receptors in the brain stem, reducing sympathetic outflow and decreasing peripheral vascular resistance, heart rate, and blood pressure.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Oral, 20 mg once daily in the morning; may increase by 10–20 mg/day at 3-day intervals up to a maximum of 60 mg/day.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
The terminal elimination half-life of methylphenidate (IR and extended-release) is approximately 3-4 hours in children and 3.5-5 hours in adults. For Aptensio XR, the half-life is about 4-5 hours, supporting twice-daily dosing.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Methylphenidate is primarily excreted renally as metabolites (80-90%), with 1-3% excreted unchanged. Biliary/fecal elimination accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant